Efficacy of Regorafenib in Metastatic Colorectal Cancer: A Multi-institutional Retrospective Study

BACKGROUND: Regorafenib is a multi-kinase inhibitor approved for treatment of refractory advanced colorectal cancer. It was found in the clinical trials to have a modest benefit and significant toxicity. Our aim was to assess the outcome in our local clinic practice. PATIENTS AND METHODS: Records of...

Descripción completa

Detalles Bibliográficos
Autores principales: Aljubran, Ali, Elshenawy, Mahmoud A, Kandil, Magdy, Zahir, Muhammed N, Shaheen, Ahmed, Gad, Ahmed, Alshaer, Omar, Alzahrani, Ahmed, Eldali, Abdelmonem, Bazarbashi, Shouki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354297/
https://www.ncbi.nlm.nih.gov/pubmed/30728734
http://dx.doi.org/10.1177/1179554918825447

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354297/
https://www.ncbi.nlm.nih.gov/pubmed/30728734
http://dx.doi.org/10.1177/1179554918825447

Ejemplares similares